Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID-19 pneumonia

Dear Editor,

As recently published, the reversal of SARS-CoV2-induced hypoxia has been demonstrated with the administration of the non-steroidal anti-inflammatory drug inhaled sodium ibuprofenate in hypertonic saline formulation (NaIHS) immersed within a compassionate use program of patients with moderate and severe Coronavirus disease 2019 (COVID-19) pneumonia in Argentina. Nonetheless, the underlying mechanisms of such effect remain unknown. Therefore, we hereby attempt to postulate the potential mechanisms upon which NaIHS exerts the aforementioned beneficial effects, possibly related to indirect inhibition of nitric oxide (NO) hyperproduction and to COVID-19 pneumonia type L. This vasoplegic form of presentation was termed type L and may present from its onset in up to 70%-80% of cases. In the above-mentioned compassionate use program, from a total of 383 patients (15% mechanically ventilated), both ventilated and non-ventilated groups experienced a rapid reversal of hypoxemia with normalization of respiratory rate, a decrease in hospitalization stay and a significant reduction in mortality in heterogeneous populations. These emerging data might suggest a pharmacological interaction associated with the short elimination half-life of gaseous NO, which is 1–5 s, and its harmful effect is concentration-dependent in micromolar range. It is noteworthy that patients with pneumonia type L might benefit from such treatment and be non-responsive to inhaled NO (iNO). Furthermore, patients with acute respiratory distress syndrome might improve with iNO or inhaled prostacycline in the presence of pulmonary hypertension, although further studies are required.

NO hyperproduction, the main vasoplegic mediator in experimental sepsis, will be described as one of its most likely determinant factors implicated in pneumonia type L, through the probable overexpression and dysregulation of NO-generating enzymes like inducible NO synthase (iNOS) and indoleamine-2,3-dioxygenase-1 (IDO). NaIHS may inhibit NO hyperproduction mainly due to its anti-inflammatory and immunomodulatory effects. It may avoid the hyperproduction of NO by indirectly inhibiting iNOS and IDO through different mechanisms, such as negatively modulating the inflammatory signalling pathways cyclooxygenase-2 (COX2), nuclear factor kappa light chain enhancer of activated B cells (NF-kB), signal transducer and activator of transcription 3 (STAT3), toll-like receptor 4 (TLR4), kynurenine, phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and the pro-inflammatory cytokines Interleukin-1 beta/-one beta. (IL-1β), tumour necrosis factor alpha (TNF-α), Interleukin-6/-six (IL-6), transforming growth factor-beta 1 (TGF-β1) and other important effects that will be further developed. Thus, NaIHS may lead to down-regulation of NO hyperproduction at monocyte and endothelial level.

We will hereby briefly describe the main pathological mechanisms related to NO hyperproduction and the potential therapeutic beneficial effects of NaIHS (Figures 1 and 2 and Table 1).

The generalized vascular hyperinflammatory status may lead to endothelial overexpression of iNOS and STAT3 and may activate the IDO and the IDO-kynurenine pathway. Under anaerobic conditions, the IDO-kynurenine pathway may produce the degradation of L-tryptophan amino acid, leading to the production of its catabolite, kynurenine, promoting up-regulation of NO. The activation of IDO may be due to positive modulation of the COX2, NF-kB, STAT3, TLR4 and the cytokines IL-1β, TNF-α and IL-6. NaIHS may produce the indirect inhibition of IDO through negative modulation of the COX2, NF-kB, STAT3, TLR4 and the cytokines IL-1β, TNF-α and IL-6. Likewise, by negatively modulating the IDO-kynurenine pathway.

Renin-angiotensin system (RAS) dysregulation is a key factor in the production of endothelitis and generalized endothelial dysfunction. It may produce angiotensin converting enzyme 2 (ACE2) down-regulation and
FIGURE 1  Pulmonary vasoplegia and hypoxemia mediated by nitric oxide (NO) hyperproduction could be explained by different pathological mechanisms. One arm shows preliminary evidence after the treatment with inhaled ibuprofenate (NaIHS), and the other arm shows evidence without the adjuvant treatment.

FIGURE 2  Potential anti-inflammatory and immunomodulatory effects of inhaled Ibuprofen in hydrosoluble formulation in COVID-19 pneumonia type L

angiotensin 2 (ang II) up-regulation. ACE2 down-regulation may promote the increase of iNOS expression with up-regulation of NO via L-arginine as its substrate, the decrease of endothelial NO synthase expression, the increase of reactivity of vascular smooth muscle to NO and the increase of the cytokines IL-6 and TNF-α. Ang II up-regulation may produce NF-kB activation through angiotensin receptor type 1, promoting iNOS and COX2 induction and expression, the increase of cytokines IL-1β, TNF-α, IL-6 and others. NaIHS may restore RAS
TABLE 1  Potential therapeutic effects of inhaled ibuprofenate leading to down-regulation of nitric oxide (NO) hyperproduction through the indirect inhibition of inducible NO synthase (iNOS) and indoleamine-2,3-dioxygenase-1 (IDO)

| Therapeutic targets | Mechanisms of action | Mechanisms of action |
|---------------------|----------------------|----------------------|
| RAS dysregulation and iNOS | Inhibition of COX-dependent effect | Inhibition of NF-kB, COX2 and TGF-β1 |
| Positive feed-back loop between inflammatory signalling pathways and pro-inflammatory cytokines and iNOS | Inhibition of COX-dependent effect | Inhibition of NF-kB, STAT3 and IL-6 |
| Warburg effect and iNOS | Inhibition of COX-dependent effect | Inhibition of PI3K/AKT/mTOR |
| Blockade of calcium entry into vascular smooth muscle cells and iNOS | Inhibition of COX-dependent effect | Inhibition of NF-kB, COX2, TNF-α, IL-1β and IL-6 |
| IDO | Inhibition of COX-dependent effect | Inhibition of STAT3, COX 2, NF-kB, TLR4, IL-1β, TNF-α and IL-6 |

Abbreviations: COX2, cyclooxygenase-2; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kappa light chain enhancer of activated B cells; RAS, renin-angiotensin system; STAT3, signal transducer and activator of transcription 3; TGF-β1, transforming growth factor-beta 1; TLR4, toll-like receptor 4.

We have herein postulated the potential mechanisms upon which NaIHS might promote reversal of hypoxemia in COVID-19 pneumonia type L that seem to be mainly related to indirect inhibition of NO hyperproduction. In this sense, NaIHS might promote restoration of hypoxic vasoconstriction, reversal of vasoplegia, correction of the decreased ventilation/perfusion mismatch and the vasoplegic shunting and therefore, the reversal of hypoxemia. On the basis of the above mentioned effects and of future randomized clinical trials, NaIHS might emerge as a potential adjuvant for COVID-19 pneumonia.

ACKNOWLEDGEMENTS
The authors offer special thanks to Mario Contin, PhD; Natalia Boucau, Certified Public Translator; Ignacio Rodriguez Sanchez, MD; Martin Kovacic, MD; Merjay Henriquez Salazar, MD; Nelson Fierro, MD; Romer Angel Torres, MD; Mirtha Laborde, MD; Gustavo Nacif, MD; Luis Gonzalez, MD and Maria Laura Mendez Marambio, whose support and contribution have made this article possible.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest to this work.

FUNDING INFORMATION
None.

Christian Carlos Zurita-Lizza1  
Pablo Alexis Doreski2

1 Hospital General de Agudos Dr. Cosme Argerich, Intensive Care Unit, Buenos Aires, Argentina
Correspondence
Christian C. Zurita-Lizza, Intensive Care Unit, Hospital General de Agudos Dr. Cosme Argerich, Pi y Margall 750 (C1155AHD), Buenos Aires, Argentina.
Email: zuritachristian70@yahoo.com.ar

ORCID
Christian Carlos Zurita-Lizza https://orcid.org/0000-0001-8969-4261

REFERENCES
1. Salva O, Doreski PA, Giler CS, et al. Reversal of SARS-CoV-2 induced hypoxia by nebulized sodium ibuprofenate in a compassionate use program. Infect Dis Ther. 2021;10(4):2511-2524. https://doi.org/10.1007/s40121-021-00527-2.
2. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med. 2020;46(6):1099-1102. https://doi.org/10.1007/s00134-020-06033-2.
3. Chilosi M, Poletti V, Ravaglia C, et al. The pathogenic role of epithelial and endothelial cells in early phase COVID-19 pneumonia: victims and partners in crime. Mod Pathol. 2021;34(8):1444-1455. https://doi.org/10.1038/s41379-021-00808-8.
4. Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131-147. https://doi.org/10.1038/s41380-019-0414-4.
5. Smart L, Fawkes N, Goggin P, et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology. 2020;28(5):1141-1152. https://doi.org/10.1007/s10787-020-00745-z.
6. Seltzer S. Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection. Int J Infect Dis. 2020;101:42-45. https://doi.org/10.1016/j.ijid.2020.09.041.
7. Kelleni MT. NSAIDs/nitazoxanide / azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther. 2021;20(1):17-21. https://doi.org/10.1080/14787210.2021.1939683.
8. Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie. 2021;180:169-177. https://doi.org/10.1016/j.biochi.2020.11.010.
9. Vallee A, Lecarpentier Y, Vallee JN. Targeting the canonical WNT/β-catenin pathway in cancer treatment using non steroidal anti-inflammatory drugs. Cells. 2019;8(7):726. https://doi.org/10.3390/cells8070726.
10. Ahmad A, Rehman MU, Ahmad P, Alkharfy KM. COVID-19 and thymoquinone: connecting the dots. Phytother Res. 2020;34(11):2786-2789. https://doi.org/10.1002/ptr.6793.